Valerio Therapeutics (XPAR:ALVIO) Other Long-Term Liabilities: €0.33 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
28 GF Score
Price €0.69
GF Value €0.07
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Valerio Therapeutics Other Long-Term Liabilities?

Valerio Therapeutics XPAR:ALVIO -2.27% 28 Other Long-Term Liabilities is €0.33 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVIO with a GF Score™ of 28/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Valerio Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2025 was €0.33 Mil.

Valerio Therapeutics's quarterly other long-term liabilities declined from Dec. 2024 (€2.04 Mil) to Jun. 2025 (€0.31 Mil) but then increased from Jun. 2025 (€0.31 Mil) to Dec. 2025 (€0.33 Mil).

Valerio Therapeutics's annual other long-term liabilities declined from Dec. 2023 (€2.12 Mil) to Dec. 2024 (€2.04 Mil) and declined from Dec. 2024 (€2.04 Mil) to Dec. 2025 (€0.33 Mil).

Valerio Therapeutics Other Long-Term Liabilities Related Terms

Valerio Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Valerio Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valerio Therapeutics Other Long-Term Liabilities Chart

Valerio Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.55 4.92 2.12 2.04 0.33

Valerio Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 4.03 2.04 0.31 0.33
XPAR:ALVIO
28GF Score
Valerio Therapeutics XPAR:ALVIO
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valerio Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €0.33 Mil mean?
Valerio Therapeutics (XPAR:ALVIO) has a Other Long-Term Liabilities of €0.33 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Valerio Therapeutics and its competitors.
Is Valerio Therapeutics' Other Long-Term Liabilities too high?
Valerio Therapeutics' current Other Long-Term Liabilities is €0.33 Mil. Overall, Valerio Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Other Long-Term Liabilities compare to VRTX and REGN?
Valerio Therapeutics' Other Long-Term Liabilities of €0.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Valerio Therapeutics and its competitors. Valerio Therapeutics's current Other Long-Term Liabilities is €0.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.69 — trading 885.7% above its estimated fair value. The current Other Long-Term Liabilities is €0.33 Mil. Valerio Therapeutics' overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Other Long-Term Liabilities is €0.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.69 is trading 885.7% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Other Long-Term Liabilities: €0.33 Mil
  • GF Value™: €0.07 vs. price of €0.69 (885.7% above fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score

Get the complete analysis for XPAR:ALVIO

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.07
GF Value